These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 32524338)

  • 21. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.
    Lee KH; Lee J; Bae JS; Kim YJ; Kang HA; Kim SH; Lee SJ; Lim KJ; Lee JW; Jung SK; Chang SJ
    MAbs; 2018 Apr; 10(3):380-396. PubMed ID: 29469653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Developer's Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10.
    Choi D; Lee S; Kim S; Yoon S
    Clin Drug Investig; 2022 Apr; 42(4):285-300. PubMed ID: 35325438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab.
    Łosińska K; Korkosz M; Pripp AH; Haugeberg G
    Rheumatol Int; 2023 May; 43(5):881-888. PubMed ID: 36922417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of switching between rituximab biosimilars in onco-hematology.
    Urru SAM; Spila Alegiani S; Guella A; Traversa G; Campomori A
    Sci Rep; 2021 Mar; 11(1):5956. PubMed ID: 33727667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
    Lee S; Lee H; Kim E
    BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe.
    Bishton M; Marshall S; Harchowal J; Salles G; Golfier C; Tucci A; Fernández AR; Sanchez Blanco JJ; Bocchia M; Kim S; Lee YN; Zinzani PL
    Hematol Oncol; 2022 Aug; 40(3):370-380. PubMed ID: 35168291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.
    Toosi R; Mahmoudi H; Balighi K; Teimourpour A; Alaeen H; Shaghaghi M; Abedini R; Daneshpazhooh M
    J Dermatolog Treat; 2021 Feb; 32(1):33-40. PubMed ID: 31074302
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunogenicity of Rituximab biosimilar GP2013 in chronic inflammatory rheumatic disorders in daily clinical practice.
    Avouac J; Cougnaud Murail R; Goulvestre C; Dumas S; Molto A; Miceli-Richard C; Conort O; Batteux F; Allanore Y
    Semin Arthritis Rheum; 2022 Feb; 52():151951. PubMed ID: 35038642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.
    De Vita S; Quartuccio L; Isola M; Mazzaro C; Scaini P; Lenzi M; Campanini M; Naclerio C; Tavoni A; Pietrogrande M; Ferri C; Mascia MT; Masolini P; Zabotti A; Maset M; Roccatello D; Zignego AL; Pioltelli P; Gabrielli A; Filippini D; Perrella O; Migliaresi S; Galli M; Bombardieri S; Monti G
    Arthritis Rheum; 2012 Mar; 64(3):843-53. PubMed ID: 22147661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.
    Tony HP; Krüger K; Cohen SB; Schulze-Koops H; Kivitz AJ; Jeka S; Vereckei E; Cen L; Kring L; Kollins D
    Arthritis Care Res (Hoboken); 2019 Jan; 71(1):88-94. PubMed ID: 30295429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
    Ogura M; Coiffier B; Kwon HC; Yoon SW
    Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis
.
    Bae SC; Lee YH
    Int J Clin Pharmacol Ther; 2019 Apr; 57(4):188-196. PubMed ID: 30574867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study.
    Buske C; Jurczak W; Sancho JM; Zhavrid E; Kim JS; Hernández-Rivas JÁ; Prokharau A; Vasilica M; Nagarkar R; Kwak L; Kim WS; Lee S; Kim S; Ahn K; Ogura M
    Blood Adv; 2021 Sep; 5(17):3354-3361. PubMed ID: 34477816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative study of efficacy and safety: Biosimilar rituximab versus originator rituximab in the treatment of pemphigus.
    Shin SH; Kim JY; Kim SC; Kim JH
    J Dermatol; 2024 Aug; 51(8):1104-1107. PubMed ID: 38874429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
    Smolen JS; Cohen SB; Tony HP; Scheinberg M; Kivitz A; Balanescu A; Gomez-Reino J; Cen L; Poetzl J; Shisha T; Kollins D
    Rheumatology (Oxford); 2021 Jan; 60(1):256-262. PubMed ID: 32699904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A non-interventional, post-marketing surveillance study evaluating the safety and effectiveness of biosimilar rituximab (CT-P10) during routine clinical practice in the Republic of Korea.
    Jo JC; Jeon Y; Kim D; Yang DH; Lee WS; Choi YS; Yi JH; Yoon DH; Kong JH; Choe JY; Kim S; Ahn K; Park T; Ju H; Kwon S; Cho SG
    Expert Opin Biol Ther; 2023; 23(8):737-747. PubMed ID: 36757373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
    Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S
    Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.
    Yoo DH; Suh CH; Shim SC; Jeka S; Cons-Molina FF; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kwon TS; Park W
    Ann Rheum Dis; 2017 Mar; 76(3):566-570. PubMed ID: 27624791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.